1. A phase I trial of VEGF-A inhibition combined with PD-L1 blockade for recurrent glioblastoma
- Author
-
Chiu, Daniel, Qi, Jingjing, Thin, Tin Htwe, Garcia-Barros, Monica, Lee, Brian, Hahn, Mary, Mandeli, John, Belani, Puneet, Nael, Kambiz, Rashidipour, Omid, Ghatan, Saadi, Hadjipanayis, Constantinos G, Yong, Raymund L, Germano, Isabelle M, Brody, Rachel, Tsankova, Nadejda M, Gnjatic, Sacha, Kim-Schulze, Seunghee, and Hormigo, Adilia
- Subjects
Brain Cancer ,Brain Disorders ,Rare Diseases ,Neurosciences ,Cancer ,Prevention ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Good Health and Well Being ,Humans ,Middle Aged ,Bevacizumab ,Glioblastoma ,Antibodies ,Monoclonal ,Vascular Endothelial Growth Factor A ,B7-H1 Antigen - Abstract
PurposeThe treatment of glioblastoma (GBM) poses challenges. The use of immune checkpoint inhibition (ICI) has been disappointing as GBM is characterized by low mutational burden and low T-cell infiltration. The combination of ICI with other treatment modalities may improve efficacy.Patient and methodsPatients with recurrent GBM were treated with avelumab, a human IgG1 antibody directed against PD-L1 (part A), or avelumab within a week after laser interstitial thermal therapy (LITT) and continuation of avelumab (part B). Bevacizumab was allowed to be combined with ICI to spare steroid use. The primary objective was to characterize the tolerability and safety of the regimens. The secondary objectives included overall survival, progression-free survival (PFS), signatures of plasma analytes, and immune cells.ResultsA total of 12 patients (median age 64; range, 37-73) enrolled, five in part A and seven in part B. Two serious adverse events occurred in the same patient, LITT treated, not leading to death. The median survival from enrollment was 13 months [95% confidence interval (CI), 4-16 months] with no differences for part A or B. The median PFS was 3 months (95% CI, 1.5-4.5 months). The decrease in MICA/MICB, γδT cells, and CD4+ T cell EMRA correlated with prolonged survival.ConclusionsAvelumab was generally well tolerated. Adding bevacizumab to ICI may be beneficial by lowering cytokine and immune cell expression. The development of this combinatorial treatment warrants further investigation. Exploring the modulation of adaptive and innate immune cells and plasma analytes as biomarker signatures may instruct future studies in this dismal refractory disease.SignificanceOur phase I of PD-L1 inhibition combined with LITT and using bevacizumab to spare steroids had a good safety profile for recurrent GBM. Developing combinatory treatment may help outcomes. In addition, we found significant immune modulation of cytokines and immune cells by bevacizumab, which may enhance the effect of ICI.
- Published
- 2023